Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia

Br J Haematol. 2021 Jul;194(2):474-477. doi: 10.1111/bjh.17479. Epub 2021 Apr 30.

Ali T Taher¹, Vip Viprakasit², Maria Domenica Cappellini³, Dominik Kraus⁴, Patrick Cech⁴, Dietmar Volz⁴, Erica Winter⁵, Stephane Nave⁴, Juergen Dukart^{4

6

7}, Omar Khwaja⁴, Annette Koerner⁴, Ricardo Hermosilla⁴, Carlo Brugnara^{8

9}

¹ Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
² Department of Pediatrics and Siriraj Thalassemia Center, Division of Hematology and Oncology, Mahidol University, Bangkok, Thailand.
³ Department of Medicine, Ca'Granda Foundation IRCCS, University of Milan, Milan, Italy.
⁴ Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
⁵ Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
⁶ Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), Research Centre Jülich, Jülich, Germany.
⁷ Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
⁸ Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA.
⁹ Department of Pathology, Harvard Medical School, Boston, MA, USA.

No abstract available

Keywords: bitopertin; haem; iron; reactive oxygen species; β-thalassemia.

Publication types

(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone
Glycine Plasma Membrane Transport Proteins
Hemoglobins
Piperazines
SLC6A9 protein, human
Sulfones